Benesch Law’s Post

Exciting milestone in European patent litigation! The recent decision by the Munich Central Division of the Unified Patent Court sets an important precedent, shaping the future of patent challenges in Europe. This ruling not only impacts the pharmaceutical industry but also has broader implications for patent strategies in various sectors. A key takeaway from UPC 1/2023 includes insights on claim interpretation, inventive step approach, claim amendments, procedural efficiency, and legal costs. Stay tuned for more updates on patent law developments and their impact on businesses. Read Julia Hornig, PhD full article here to find out more on this decision: https://lnkd.in/eAeU8YwX #UPC #PatentLitigation #EuropeanLaw 

We are happy to share that #VOSSIUS is ranked by Leaders League in the following categories: ▪ Patent Litigation ▪ Patent Prosecution ▪ Trademark Litigation ▪ Trademark Prosecution ▪ Healthcare, pharmaceuticals & biotech We highly appreciate the recognition of our work. www.vossius.eu #leadersleague #ranking #intellectualproperty #biotech #iplaw

There is still time to sign up for our webinar in conjunction with SwedenBIO discussing pharma patent enforcement and litigation in Asia. Led by Nick Redfearn and Terry LU, it will examine patent invalidation, administrative litigation and drug patent linkage litigation in China. #pharma #pharmaceuticals #China #patents #litigation

Thoughts on this? >> Amicus stock jumps after resolution of Galafold patent litigation against Teva >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #biotech #productmarketing

Thoughts on this? >> Amicus stock jumps after resolution of Galafold patent litigation against Teva >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #biotech #pharmaceutical

What made The Pharma and Biotech Patent Litigation Summit 2024 so great? Over 450 attendees and 80+ speakers for 3 days of practical discussion surrounding the leading patent litigation topics in Europe, with a compare and contrast method with jurisdictions further afield. Our attendees left with the necessary practical tools to both defend patent litigation challenges for their pharma and biotech product, whilst also maximising their litigation strategy to allow for successful IP protection. With so much to reflect on from this year's summit, we've created a 2024 recap page on our website that includes our audience breakdown, top highlights interviews, and key take aways from our attendees and partners! Get your 2024 recap here: https://lnkd.in/eh9xHyKv Now we look to 2025 for Europe’s leading pharmaceutical and biotech event to define, shape and create successful patent strategies and mitigate risks. Register your interest for 2025 here: https://lnkd.in/e3XsABn9 #patlit #patent #litigation #recap

Partner and Chair of Katten’s global Intellectual Property practice Deepro Mukerjee will speak on "The Business of PIV Disputes — Global IP Risks — Effectively Managing an International Pharmaceutical IP Litigation Strategy" on Friday, April 26, during the American Conference Institute’s 20th Annual Paragraph IV Disputes Conference. His session will discuss how to navigate the complex landscape of international IP litigation in the Hatch-Waxman context, including strategies for managing cross-border IP risks and ways to align one’s global strategy with business objectives. #IPLaw #LegalEvents #PIVDisputes #IPRisk #IntellectualProperty

🚨 Victory for Sun Pharmaceuticals in opposition proceedings! 🚨 I'm happy to share that, together with my colleague Ksenia Emelianova (PhD, patent attorney), we successfully represented Sun Pharmaceuticals in revoking key claims of Novo Nordisk's patent RU 2421238 on liraglutide formulations used in Victoza and Saxenda as anti-diabetic and weight loss drugs. The decision by the Chamber for Patent Disputes of September 30, 2024 reaffirms the important principles regarding the novelty requirement under Russian patent law. It also underlines the critical importance of a sound IP strategy during R&D. I’m thrilled to see our hard work pay off for our client. 💡 Key Takeaway: This case highlights how earlier filings by the same patent holder can affect future applications. Navigating the complexities of IP law, especially across different jurisdictions, requires foresight and an understanding of evolving standards. Curious how this might impact your IP strategy? Let’s connect! Feel free to reach out, or comment below with your thoughts on navigating patent challenges internationally. More details about the case can be found on the Patentica's website here: https://lnkd.in/dsR_QZKQ #IntellectualProperty #PatentLaw #PatentDisputes #IPStrategy #Pharmaceuticals #PatentAttorneys #InternationalLaw #PatentProtection

Partner and Chair of Katten’s global Intellectual Property practice Deepro R. Mukerjee will speak on "The Business of PIV Disputes — Global IP Risks — Effectively Managing an International Pharmaceutical IP Litigation Strategy" on Friday, April 26, during the American Conference Institute’s 20th Annual Paragraph IV Disputes Conference. His session will discuss how to navigate the complex landscape of international IP litigation in the Hatch-Waxman context, including strategies for managing cross-border IP risks and ways to align one’s global strategy with business objectives. #IPLaw #LegalEvents #PIVDisputes #IPRisk #IntellectualProperty

Our recent 𝘚𝘢𝘯𝘰𝘧𝘪 v 𝘈𝘮𝘨𝘦𝘯 article illustrated how results can differ in pharmaceutical patent disputes depending on the jurisdiction. This joint webinar with our Smart & Biggar colleagues will explore how some key aspects of patent law and litigation have been applied differently in Canada and Australia, and how this impacts on running litigation, and potentially outcome, in these jurisdictions. Designed to assist IP litigators, managers and owners, particularly those in European or US jurisdictions, four leading patent litigators will look at infringement - including skinny labelling and claim structures - and obviousness. 👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲 for the session that best suits your schedule: https://direc.to/mdP9 Meet the speakers: ⭐ Katrina Crooks, Principal, Head of Spruson & Ferguson Lawyers ⭐ Duncan Longstaff, Principal, Spruson & Ferguson Lawyers ⭐ Urszula Wojtyra, Principal, Smart & Biggar ⭐ J. Sheldon Hamilton, Principal, Smart & Biggar #pharmaceutical #pharmaceuticalpatents #patentlitigation #IPstrategy #intellectualproperty #Canada #Australia